Study guide
8.2 Medications for Alcohol and Tobacco Use Disorders
IC&RC Advanced Alcohol & Drug Counselor AADC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Master's-Level Credentialing
1.1 IC&RC AADC Exam Purpose, Structure & Scoring 1.2 Master's-Level Preparation Strategy & Exam Blueprint Navigation
2 Chapter 2: Diagnostic Systems & DSM-5-TR Substance Use Disorders
2.1 DSM-5-TR Diagnostic Criteria & Severity Continuum 2.2 Substance Classes, Intoxication & Withdrawal Syndromes 2.3 Neurobiology of Addiction & Tolerance Mechanics
3 Chapter 3: Standardized Screening, Comprehensive Assessment & Diagnostic Feedback
3.1 Clinical Distinctions Between Screening and Assessment 3.2 Evidence-Based Assessment Instruments 3.3 Selecting Culturally Appropriate Screening and Assessment Tools 3.4 Biopsychosocial Intake Interviewing & Stage-of-Change Assessment 3.5 Documenting Screening and Assessment Results 3.6 Discussing Diagnostic Results and Recommendations
4 Chapter 4: Complex Co-Occurring Psychiatric Disorders & Differential Diagnosis
4.1 Differential Diagnosis Principles: Primary vs Substance-Induced Disorders 4.2 Co-Occurring Depressive, Bipolar & Anxiety Disorders 4.3 Personality Disorders, PTSD & Severe Mental Illness
5 Chapter 5: Trauma, Suicide Risk & Crisis Engagement
5.1 Trauma Assessment & Complex Post-Traumatic Stress 5.2 Lethality & Suicide Risk Formulation 5.3 Crisis Intervention & Motivational Engagement
6 Chapter 6: ASAM Criteria & Multidimensional Level of Care Placement
6.1 ASAM Six Assessment Dimensions 6.2 ASAM Continuum of Care Levels 6.3 Level-of-Care Transitions, Continued Stay & Discharge
7 Chapter 7: Treatment Planning & SMART Goal Formulation
7.1 Problem Identification & Clinical Formulation 7.2 SMART Goals, Objectives & Interventions 7.3 Treatment Plan Evolution, Ongoing Review & Documentation 7.4 Educating the Person Served About the Counseling Process
8 Chapter 8: Pharmacotherapy & Medications for Substance Use Disorders
8.1 Medications for Opioid Use Disorder (MOUD) 8.2 Medications for Alcohol and Tobacco Use Disorders 8.3 Psychiatric Pharmacotherapy & The Counselor's Role
9 Chapter 9: Interprofessional Collaboration, Care Coordination & Referral
9.1 Multidisciplinary Teamwork & Integrated Healthcare 9.2 Referral Processes & Continuity of Care 9.3 Coordination with Specialized Systems
10 Chapter 10: Cognitive Behavioral Therapy & Relapse Prevention
10.1 Theoretical Foundations of CBT in Addiction 10.2 Cognitive Restructuring & Behavioral Coping Skills 10.3 Relapse Prevention Models & The Abstinence Violation Effect 10.4 Community Reinforcement & Third-Wave CBT Approaches
11 Chapter 11: Motivational Interviewing & Motivational Enhancement Therapy
11.1 Spirit & Foundational Principles of Motivational Interviewing 11.2 Four Processes & OARS Core Clinical Skills 11.3 Motivational Enhancement Therapy Protocol & Change Talk
12 Chapter 12: Contingency Management, Twelve-Step Facilitation & Third-Wave Behavioral Approaches
12.1 Operant Conditioning & Contingency Management Protocols 12.2 Twelve-Step Facilitation (TSF) Therapy 12.3 Mindfulness-Based Relapse Prevention (MBRP) & Acceptance Approaches 12.4 Multiple Pathways of Recovery & Adapting Intervention Strategies
13 Chapter 13: Family Systems, Adolescent Considerations & Group Psychotherapy
13.1 Family Systems Approaches in Addiction Treatment 13.2 Adolescent-Specific Assessment & Evidence-Based Interventions 13.3 Group Psychotherapy Dynamics & Facilitation
14 Chapter 14: Psychoeducation, Health Promotion & Infectious Disease
14.1 Medical & Health Consequences of Chronic Substance Use 14.2 Infectious Diseases: HIV/AIDS, Viral Hepatitis & STI Transmission 14.3 Wellness, Lifestyle Modification & Holistic Recovery Support
15 Chapter 15: Confidentiality, 42 CFR Part 2 & Legal Mandates
15.1 Federal Confidentiality Laws: 42 CFR Part 2 Foundations 15.2 Comparing 42 CFR Part 2 and HIPAA: Consent & Disclosures 15.3 Medical Emergencies, Child/Elder Abuse & Mandated Reporting 15.4 Duty to Warn (Tarasoff) & Responding to Subpoenas and Court Orders
16 Chapter 16: Clinical Supervision Models, Competency Evaluation & Gatekeeping
16.1 Theoretical Frameworks & Models of Clinical Supervision 16.2 The Supervisory Relationship, Roles & Modalities 16.3 Competency Evaluation, Formative Feedback & Gatekeeping 16.4 Vicarious Liability, Legal Risks & Managing Impaired Counselors
17 Chapter 17: Professional Ethics, Boundaries & Multicultural Competence
17.1 Professional Codes of Ethics & Ethical Decision-Making Frameworks 17.2 Dual Relationships, Professional Boundaries & Conflict of Interest 17.3 Multicultural Competence, Cultural Humility & Health Disparities 17.4 Technology, Telehealth & Digital Ethics in Addiction Counseling 17.5 Integrating Research Into Clinical Practice
8.2 Medications for Alcohol and Tobacco Use Disorders
Key Takeaways Explain This Topic AI
Acamprosate (Campral) restores the neurochemical balance between excitatory glutamate (NMDA) and inhibitory GABA transmission, attenuating protracted post-acute withdrawal, and is eliminated renally, making it safe in hepatic cirrhosis but contraindicated in severe renal impairment (eGFR < 30 mL/min).
Disulfiram (Antabuse) functions as an irreversible aldehyde dehydrogenase (ALDH) inhibitor that produces severe toxic acetaldehyde accumulation (the disulfiram-ethanol reaction) upon alcohol ingestion, requiring cognitive competence, strict client selection, and absolute sobriety before initiation.
Naltrexone (oral ReVia and depot Vivitrol) blocks endogenous mu-opioid reward pathways, reducing alcohol craving and blunting the reinforcing high of heavy drinking, but requires baseline liver function monitoring.
First-line pharmacotherapies for Tobacco Use Disorder include five Nicotine Replacement Therapy (NRT) formulations, varenicline (alpha-4 beta-2 partial agonist), and bupropion SR (NDRI), with combination NRT and varenicline exhibiting the highest clinical cessation rates.
Bupropion SR is strictly contraindicated in clients with current or historical anorexia nervosa, bulimia, active seizure disorders, or undergoing acute withdrawal from alcohol or sedatives due to severe seizure threshold reduction.
Last updated: September 2026
8.2 Medications for Alcohol and Tobacco Use Disorders
Important
Targeting Neurochemical Adaptations in AUD and TUD : Chronic consumption of alcohol and nicotine induces profound neuroadaptive changes across multiple central neurotransmitter circuits. Pharmacotherapies for Alcohol Use Disorder (AUD) and Tobacco Use Disorder (TUD) target these neuroadaptations: restoring homeostatic balance between excitatory glutamate (NMDA) and inhibitory gamma-aminobutyric acid (GABA) transmission, blocking endogenous opioid reinforcement, inducing severe aversive physical reactions to ethanol, or competitively modulating nicotinic acetylcholine receptors. Advanced addiction counselors must master the distinct pharmacological mechanisms, organ clearance pathways, and strict contraindications of these life-saving medications.
While pharmacotherapy is widely accepted for opioid use disorder, medications for Alcohol Use Disorder and Tobacco Use Disorder remain significantly underutilized in clinical practice. Master's-level addiction counselors must understand the empirical mechanisms, client selection criteria, and medical contraindications of these medications to provide competent psychoeducation, facilitate collaborative medical referrals, and optimize treatment adherence.
Pharmacotherapy for Alcohol Use Disorder (AUD)
Chronic heavy alcohol exposure fundamentally disrupts the central nervous system's homeostatic balance by chronically enhancing inhibitory GABAA neurotransmission while suppressing excitatory N-methyl-D-aspartate (NMDA) glutamate receptors. In response, the brain up-regulates NMDA receptors and down-regulates GABAA receptors. When alcohol is abruptly discontinued, the individual experiences severe glutamate-mediated neurotoxicity and autonomic hyperactivity. The three FDA-approved medications for AUD address these pathways through distinct clinical strategies: +-----------------------------------------------------------------------------------+
- | FDA-APPROVED PHARMACOTHERAPIES FOR ALCOHOL USE DISORDER |
- +-----------------------------------------------------------------------------------+
- | 1. ACAMPROSATE (Campral) -> Modulates NMDA/GABA; clears protracted withdrawal |
- | 2. DISULFIRAM (Antabuse) -> Irreversibly blocks ALDH; aversive conditioning |
- | 3. NALTREXONE (ReVia / Vivitrol) -> Blocks mu receptors; extinguishes reward |
- +-----------------------------------------------------------------------------------+
- Acamprosate (Campral): Neurochemical Stabilization & Protracted Withdrawal
Acamprosate (calcium bisacetylhomotaurinate) is a synthetic amino acid derivative chemically resembling GABA:
Mechanism of Action : Functions as a neuromodulator that dampens hyperactive NMDA glutamate receptor transmission while subtly enhancing GABAA receptor tone. It does not treat acute alcohol withdrawal, but rather stabilizes post-acute neurochemical hyperarousal, mitigating Post-Acute Withdrawal Syndrome (PAWS) symptoms such as chronic insomnia, anxiety, dysphoria, autonomic restlessness, and persistent craving.
Organ Clearance & Safety Profile : Acamprosate is excreted completely unchanged by the kidneys through glomerular filtration. It undergoes zero hepatic metabolism and is completely non-hepatotoxic. This makes acamprosate the medication of choice for clients with significant hepatic impairment, alcoholic hepatitis, or decompensated liver cirrhosis .
Contraindications : Absolutely contraindicated in clients with severe renal impairment ( creatinine clearance / eGFR < 30 mL/min ). Requires dose reduction in moderate renal insufficiency (eGFR 30–50 mL/min).
Adherence Considerations : Standard adult dosing is 666 mg three times daily (TID) (two 333 mg delayed-release tablets taken three times a day with meals). The requirement to ingest six large pills daily represents a significant adherence hurdle, requiring structured behavioral routines and counselor monitoring.
Disulfiram (Antabuse): Aversive Conditioning via ALDH Inhibition
Disulfiram represents the classical psychological deterrent and aversive conditioning agent in addiction medicine:
Pharmacodynamics : Irreversibly inhibits hepatic aldehyde dehydrogenase (ALDH) , the key enzyme responsible for converting acetaldehyde into harmless acetic acid during alcohol metabolism.
The Disulfiram-Ethanol Reaction (DER) : When an individual taking disulfiram ingests even minute quantities of ethanol, blood levels of toxic acetaldehyde surge 5- to 10-fold within 5 to 15 minutes. This creates an excruciating physical reaction characterized by intense facial flushing, throbbing headache, diaphoresis, dyspnea, violent nausea and vomiting, palpitations, tachycardia, and severe hypotension. In extreme cases, the reaction can progress to cardiac arrhythmias, acute myocardial infarction, cardiovascular collapse, seizures, and death.
Duration of Effect : Because disulfiram inhibits ALDH irreversibly, new enzyme synthesis is required for recovery; the potential for a DER persists for up to 14 days after discontinuing the medication.
Clinical Selection & Absolute Contraindications : Disulfiram carries zero effect on alcohol cravings. It functions purely as an external psychological barrier and is effective primarily under directly observed administration (e.g., administered daily by a spouse, clinic nurse, or probation officer). The client must have intact cognitive functioning to comprehend the fatal risks and must achieve verified zero blood alcohol for at least 12 to 24 hours prior to initiation. Disulfiram is strictly contraindicated in coronary artery disease, history of myocardial infarction, congestive heart failure, active psychosis (inhibits dopamine beta-hydroxylase, elevating dopamine and worsening psychosis), severe hepatic failure, and pregnancy .
Hidden Alcohol Education : Clinicians must rigorously educate clients to avoid everyday products containing concealed ethanol, including over-the-counter cough syrups, mouthwashes, cooking vinegars, fermented sauces, aftershave lotions, and hand sanitizers.
Naltrexone (Oral ReVia & Depot Vivitrol) for Alcohol Dependence
Mechanism of Action : Chronic alcohol ingestion stimulates the release of endogenous beta-endorphins, which bind to mu-opioid receptors in the VTA, disinhibiting dopaminergic neurons and producing a reinforcing euphoric "high." Naltrexone acts as a competitive mu-opioid receptor antagonist , blocking endorphin binding and disconnecting alcohol consumption from dopaminergic reinforcement.
Clinical Outcome : Naltrexone significantly reduces alcohol cravings, cuts the frequency of drinking days, and prevents a minor "slip" from escalating into a full-blown relapse or heavy binge drinking episode. Some clinical protocols (e.g., the Sinclair Method) specifically utilize targeted oral naltrexone taken 1 hour prior to drinking to facilitate pharmacological extinction of conditioned reward.
Formulations : Available as a 50 mg once-daily oral tablet (ReVia) or as a 380 mg once-monthly intramuscular gluteal depot injection (Vivitrol) . The monthly depot formulation entirely overcomes daily oral compliance barriers.
Monitoring & Contraindications : Naltrexone undergoes hepatic metabolism. While safe at standard therapeutic doses, baseline and periodic liver function tests (LFTs) are standard of care, and it is contraindicated in acute hepatitis or liver failure (serum transaminases > 3–5 times the upper limit of normal). Naltrexone is absolutely contraindicated in anyone taking opioid analgesics or undergoing opioid withdrawal .
Pharmacotherapy for Tobacco Use Disorder (TUD)
Tobacco Use Disorder remains the leading cause of preventable morbidity and mortality worldwide. First-line pharmacotherapies include three distinct classes:
Nicotine Replacement Therapy (NRT)
NRT provides clean, controlled doses of nicotine without the thousands of carcinogenic toxins and carbon monoxide present in combustible tobacco smoke. Available in five FDA-approved forms:
Transdermal Patch : Long-acting; provides continuous, steady-state baseline blood nicotine levels over 16 to 24 hours.
Nicotine Gum : Short-acting; absorbed transmucosally; requires the "chew-and-park" technique (chew until peppery taste or tingle, then park between cheek and gum).
Nicotine Lozenge : Short-acting; dissolves slowly in the buccal mucosa without chewing.
Nicotine Nasal Spray : Rapid mucosal absorption; fastest peak blood levels mimicking cigarette kinetics; high potential for sensory irritation (sneezing, watery eyes).
Nicotine Oral Inhaler : Delivers nicotine vapor to the buccal mucosa; replicates the behavioral hand-to-mouth ritual.
Combination NRT Superiority : Clinical practice guidelines strongly recommend combination NRT (pairing a long-acting transdermal patch for baseline stabilization with a short-acting form like gum or lozenge for acute breakthrough cravings) over monotherapy, yielding significantly higher long-term cessation rates.
Varenicline (Chantix): Nicotinic Receptor Partial Agonism
Mechanism : A high-affinity partial agonist at alpha-4 beta-2 (α4β2) neuronal nicotinic acetylcholine receptors in the brain's reward center:
Agonist effect : Sub-maximally stimulates the receptor, evoking moderate dopamine release to alleviate withdrawal symptoms and suppress intense cravings.
Antagonist effect : Because of its extremely high binding affinity, it competitively blocks inhaled nicotine from binding. If the client smokes a cigarette, they experience zero reinforcing reward.
Clinical Administration & Side Effects : Initiated 1 to 2 weeks prior to a client's target quit date and titrated to 1 mg twice daily. Most common adverse effects include nausea (mitigated by taking with food and a full glass of water), insomnia, and abnormal/vivid dreams.
Neuropsychiatric Safety : While previously carrying a boxed warning, the landmark EAGLES clinical trial demonstrated that varenicline does not significantly increase neuropsychiatric events compared to placebo or NRT, establishing it as the single most effective oral monotherapy for smoking cessation.
Bupropion SR (Zyban / Wellbutrin): Norepinephrine-Dopamine Reuptake Inhibition
Mechanism : A monocyclic aminoketone functioning as an inhibitor of norepinephrine and dopamine reuptake (NDRI) with non-competitive antagonism at nicotinic acetylcholine receptors. It attenuates nicotine withdrawal symptoms and reduces post-cessation weight gain.
Dosing : Initiated 1 to 2 weeks prior to the target quit date at 150 mg once daily for 3 days, then titrated to 150 mg twice daily (spaced at least 8 hours apart to prevent seizure risk).
Absolute Contraindications : Bupropion lowers the cerebral seizure threshold. It is strictly contraindicated in clients with a current or prior diagnosis of anorexia nervosa or bulimia nervosa (due to significantly elevated seizure incidence), active seizure disorders, concurrent administration of MAO inhibitors, or undergoing abrupt discontinuation of alcohol, benzodiazepines, or other sedatives .
AUD Medications Comparison Matrix
Medication Primary Neurochemical Target Formulation & Dosing Primary Clearance Clinical Utility & Indication Major Contraindications & Warnings
Acamprosate (Campral) NMDA glutamate antagonist; GABAA modulator Oral 666 mg TID (two 333 mg tabs three times daily) 100% Renal (Unchanged) Maintenance of abstinence; clears post-acute withdrawal (PAWS) Severe renal impairment (eGFR < 30 mL/min). Safe in severe liver disease.
Disulfiram (Antabuse) Irreversible Aldehyde Dehydrogenase (ALDH) inhibitor Oral 250–500 mg once daily Hepatic Aversive behavioral deterrent; highly effective under direct observation Coronary artery disease, heart failure, psychosis, pregnancy, severe hepatic failure.
Naltrexone (Oral) (ReVia) Competitive mu-opioid receptor antagonist Oral 50 mg once daily Hepatic Reduces cravings; blunts heavy drinking days; promotes extinction Concurrent opioid use; acute hepatitis or acute liver failure (LFT > 3–5x ULN).
Naltrexone (Depot) (Vivitrol) Competitive mu-opioid receptor antagonist Intramuscular 380 mg depot every 4 weeks Hepatic Eliminates oral adherence barriers; extinguishes alcohol reward Concurrent opioid use; severe hepatic failure; injection-site tissue reactions.
Tobacco Cessation Pharmacotherapy Matrix
Agent Pharmacological Mechanism Clinical Administration Common Adverse Effects High-Yield Exam Contraindications
Transdermal Patch Continuous steady-state nicotine delivery 21 mg, 14 mg, 7 mg steps applied daily Skin erythema, vivid dreams, insomnia Immediate post-myocardial infarction (<2 weeks), severe arrhythmias.
Short-Acting NRT (Gum, Lozenge, Spray, Inhaler) Rapid buccal or nasal mucosal absorption PRN for acute craving spikes (every 1–2 hrs) Dyspepsia, mouth irritation, hiccoughs Temporomandibular joint (TMJ) disease (gum); severe asthma (inhaler/spray).
Varenicline (Chantix) α4β2 nicotinic acetylcholine receptor partial agonist 0.5 mg daily titrating to 1 mg BID; start 1–2 wks pre-quit Nausea, vivid dreams, insomnia, headache End-stage renal disease (dose reduce); monitor for neuropsychiatric changes.
Bupropion SR (Zyban) Norepinephrine-dopamine reuptake inhibitor (NDRI) 150 mg daily x 3 days, then 150 mg BID; start 1–2 wks pre-quit Insomnia, dry mouth, agitation, tremors Seizure history, current/past bulimia or anorexia nervosa, acute alcohol/sedative withdrawal.
Clinical Contraindications & Safety Assessment Guide
When evaluating clients for AUD and TUD pharmacotherapy referrals, master's-level counselors must systematically screen for black-letter medical contraindications:
Renal vs. Hepatic Cleaving : Check recent metabolic panels. If serum creatinine is significantly elevated or eGFR < 30 mL/min, acamprosate is contraindicated ; consider naltrexone. If AST/ALT are markedly elevated or cirrhosis is present, naltrexone and disulfiram are risky or contraindicated ; acamprosate is the drug of choice .
Cardiovascular & Psychiatric Screening for Disulfiram : Never support disulfiram in clients with angina, prior bypass/stents, heart failure, cognitive deficits, or history of psychosis or active depression.
Seizure & Eating Disorder Screening for Bupropion : Inquire specifically about adolescent or adult history of purging, restrictive eating, or unprovoked seizures before supporting bupropion referrals.